Literature DB >> 8879431

Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease.

M R Malinow1, P Ducimetiere, G Luc, A E Evans, D Arveiler, F Cambien, B M Upson.   

Abstract

Standardized mortality rates for coronary heart disease (CHD) in men are about 3-fold higher in Northern Ireland than in France. The differences could not be explained by the presence of conventional risk factors for atherosclerosis. We studied in subjects from these two countries, an additional risk factor, namely, concentration of plasma homocyst(e)ine which is frequently elevated in patients with CHD. We measured the plasma concentration of homocyst(e)ine in survivors of myocardial infarction (MI) and in control subjects from the Belfast, Strasbourg and Lille regions. Plasma homocyst(e)ine levels were higher in the Irish than in the French controls; subjects with MI had higher levels than controls. Results were compatible with global excess of risk for MI being graded across the distribution of plasma homocyst(e)ine concentrations, although the trends lost significance in Belfast after adjustment for other risk factors. The higher plasma homocyst(e)ine concentrations we observed in the Irish population could be the reason for the different CHD mortality rates. This epidemiological observation could prompt dietary and vitamin supplementation studies aimed at decreasing homocyst(e)ine levels as well as the incidence of arterial occlusive disease, under controlled conditions in high risk populations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8879431     DOI: 10.1016/0021-9150(96)05890-x

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

1.  [Homocysteine as a cardiovascular marker and risk factor].

Authors:  K Pietrzik
Journal:  Clin Res Cardiol       Date:  2006       Impact factor: 5.460

Review 2.  [Laboratory diagnosis in preventive cardiology].

Authors:  M Soufi; B Noll; M Herzum; B Simon; A Steinmetz; B Maisch; J R Schaefer
Journal:  Herz       Date:  1999-02       Impact factor: 1.443

Review 3.  Homocysteine, vitamins, and coronary artery disease. Comprehensive review of the literature.

Authors:  B V Taylor; G Y Oudit; M Evans
Journal:  Can Fam Physician       Date:  2000-11       Impact factor: 3.275

4.  Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care.

Authors:  G L Booth; E E Wang
Journal:  CMAJ       Date:  2000-07-11       Impact factor: 8.262

5.  Plasma Homocysteine is a Predictive Factor for Arterial Stiffness: A Community-Based 4.8-Year Prospective Study.

Authors:  Xiao-Na Wang; Ping Ye; Rui-Hua Cao; Xu Yang; Wen-Kai Xiao; Yun Zhang; Yong-Yi Bai; Hong-Mei Wu
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-04-20       Impact factor: 3.738

6.  Correlation between cystathionine β-synthase T883C genetic polymorphism and primary hypertension.

Authors:  Ying Zhang; Hong Wang; Huan-Wen Sun; Yu-Lan Chen; Ju-Yan Ouyang; Yu Wang; Ling Wang; Xiang-Yang Zhang
Journal:  Exp Ther Med       Date:  2014-06-23       Impact factor: 2.447

7.  The association of homocysteine with metabolic syndrome in a community-dwelling population: homocysteine might be concomitant with metabolic syndrome.

Authors:  Xiaona Wang; Ping Ye; Ruihua Cao; Xu Yang; Wenkai Xiao; Yun Zhang; Yongyi Bai; Hongmei Wu
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

8.  Homocysteine is associated with higher risks of ischemic stroke: A systematic review and meta-analysis.

Authors:  Nícollas Nunes Rabelo; João Paulo Mota Telles; Leonardo Zumerkorn Pipek; Rafaela Farias Vidigal Nascimento; Rodrigo Coimbra de Gusmão; Manoel Jacobsen Teixeira; Eberval Gadelha Figueiredo
Journal:  PLoS One       Date:  2022-10-13       Impact factor: 3.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.